317 related articles for article (PubMed ID: 30388809)
41. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
42. Arterial stiffness induces remodeling phenotypes in pulmonary artery smooth muscle cells via YAP/TAZ-mediated repression of cyclooxygenase-2.
Dieffenbach PB; Haeger CM; Coronata AMF; Choi KM; Varelas X; Tschumperlin DJ; Fredenburgh LE
Am J Physiol Lung Cell Mol Physiol; 2017 Sep; 313(3):L628-L647. PubMed ID: 28642262
[TBL] [Abstract][Full Text] [Related]
43. Magnolol attenuates VCAM-1 expression in vitro in TNF-alpha-treated human aortic endothelial cells and in vivo in the aorta of cholesterol-fed rabbits.
Chen YH; Lin SJ; Chen JW; Ku HH; Chen YL
Br J Pharmacol; 2002 Jan; 135(1):37-47. PubMed ID: 11786478
[TBL] [Abstract][Full Text] [Related]
44. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
45. YAP and TAZ are distinct effectors of corneal myofibroblast transformation.
Muppala S; Raghunathan VK; Jalilian I; Thomasy S; Murphy CJ
Exp Eye Res; 2019 Mar; 180():102-109. PubMed ID: 30578787
[TBL] [Abstract][Full Text] [Related]
46. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.
Horie M; Saito A; Ohshima M; Suzuki HI; Nagase T
Cancer Sci; 2016 Dec; 107(12):1755-1766. PubMed ID: 27627196
[TBL] [Abstract][Full Text] [Related]
47. YAP/TAZ-CDC42 signaling regulates vascular tip cell migration.
Sakabe M; Fan J; Odaka Y; Liu N; Hassan A; Duan X; Stump P; Byerly L; Donaldson M; Hao J; Fruttiger M; Lu QR; Zheng Y; Lang RA; Xin M
Proc Natl Acad Sci U S A; 2017 Oct; 114(41):10918-10923. PubMed ID: 28973878
[TBL] [Abstract][Full Text] [Related]
48. YAP promotes endothelial barrier repair by repressing STAT3/VEGF signaling.
Fan X; Shan X; Jiang S; Wang S; Zhang F; Tian Q; Chen D; Ma J; Xue F; Mao S; Fan J; Wang Y; Gong Y
Life Sci; 2020 Sep; 256():117884. PubMed ID: 32502546
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis.
Toyama T; Looney AP; Baker BM; Stawski L; Haines P; Simms R; Szymaniak AD; Varelas X; Trojanowska M
J Invest Dermatol; 2018 Jan; 138(1):78-88. PubMed ID: 28870693
[TBL] [Abstract][Full Text] [Related]
50. STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling.
Zheng L; Xiang C; Li X; Guo Q; Gao L; Ni H; Xia Y; Xi T
J Hematol Oncol; 2018 May; 11(1):72. PubMed ID: 29848346
[TBL] [Abstract][Full Text] [Related]
51. YAP Controls Endothelial Activation and Vascular Inflammation Through TRAF6.
Lv Y; Kim K; Sheng Y; Cho J; Qian Z; Zhao YY; Hu G; Pan D; Malik AB; Hu G
Circ Res; 2018 Jun; 123(1):43-56. PubMed ID: 29794022
[TBL] [Abstract][Full Text] [Related]
52. Type I collagen deposition via osteoinduction ameliorates YAP/TAZ activity in 3D floating culture clumps of mesenchymal stem cell/extracellular matrix complexes.
Komatsu N; Kajiya M; Motoike S; Takewaki M; Horikoshi S; Iwata T; Ouhara K; Takeda K; Matsuda S; Fujita T; Kurihara H
Stem Cell Res Ther; 2018 Dec; 9(1):342. PubMed ID: 30526677
[TBL] [Abstract][Full Text] [Related]
53. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
Lamar JM; Xiao Y; Norton E; Jiang ZG; Gerhard GM; Kooner S; Warren JSA; Hynes RO
J Biol Chem; 2019 Feb; 294(7):2302-2317. PubMed ID: 30559289
[TBL] [Abstract][Full Text] [Related]
54. Involvement of YAP, TAZ and HSP90 in contact guidance and intercellular junction formation in corneal epithelial cells.
Raghunathan VK; Dreier B; Morgan JT; Tuyen BC; Rose BW; Reilly CM; Russell P; Murphy CJ
PLoS One; 2014; 9(10):e109811. PubMed ID: 25290150
[TBL] [Abstract][Full Text] [Related]
55. YAP/TAZ regulates the expression of proteoglycan 4 and tenascin C in superficial-zone chondrocytes.
Delve E; Co V; Regmi SC; Parreno J; Schmidt TA; Kandel RA
Eur Cell Mater; 2020 Jan; 39():48-64. PubMed ID: 31917459
[TBL] [Abstract][Full Text] [Related]
56. Propionate reduces the cytokine-induced VCAM-1 and ICAM-1 expression by inhibiting nuclear factor-kappa B (NF-kappaB) activation.
Zapolska-Downar D; Naruszewicz M
J Physiol Pharmacol; 2009 Jun; 60(2):123-31. PubMed ID: 19617655
[TBL] [Abstract][Full Text] [Related]
57. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.
Hansen CG; Ng YL; Lam WL; Plouffe SW; Guan KL
Cell Res; 2015 Dec; 25(12):1299-313. PubMed ID: 26611634
[TBL] [Abstract][Full Text] [Related]
58. Lycopene inhibits TNF-alpha-induced endothelial ICAM-1 expression and monocyte-endothelial adhesion.
Hung CF; Huang TF; Chen BH; Shieh JM; Wu PH; Wu WB
Eur J Pharmacol; 2008 May; 586(1-3):275-82. PubMed ID: 18439578
[TBL] [Abstract][Full Text] [Related]
59. Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma.
Bouvier C; Macagno N; Nguyen Q; Loundou A; Jiguet-Jiglaire C; Gentet JC; Jouve JL; Rochwerger A; Mattei JC; Bouvard D; Salas S
Oncotarget; 2016 Oct; 7(40):64702-64710. PubMed ID: 27608849
[TBL] [Abstract][Full Text] [Related]
60. Irbesartan attenuates TNF-α-induced ICAM-1, VCAM-1, and E-selectin expression through suppression of NF-κB pathway in HUVECs.
Jiang Y; Jiang LL; Maimaitirexiati XM; Zhang Y; Wu L
Eur Rev Med Pharmacol Sci; 2015 Sep; 19(17):3295-302. PubMed ID: 26400537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
